Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. CYP2C19 Antibody

CYP2C19 Antibody

  • 中文名稱：
    CYP2C19兔多克隆抗體
  • 貨號(hào)：
    CSB-PA006417LA01HU
  • 規(guī)格：
    ￥440
  • 促銷：
    小規(guī)格抗體限時(shí)一口價(jià)
  • 圖片：
    • Western Blot
      Positive WB detected in: Mouse kidney tissue
      All lanes: CYP2C19 antibody at 4μg/ml
      Secondary
      Goat polyclonal to rabbit IgG at 1/50000 dilution
      Predicted band size: 56 kDa
      Observed band size: 56 kDa
    • IHC image of CSB-PA006417LA01HU diluted at 1:400 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
    • IHC image of CSB-PA006417LA01HU diluted at 1:400 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
    • Immunofluorescence staining of Hela cells with CSB-PA006417LA01HU at 1:133, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品名稱：
    Rabbit anti-Homo sapiens (Human) CYP2C19 Polyclonal antibody
  • Uniprot No.：
  • 基因名：
    CYP2C19
  • 別名：
    (R)-limonene 6-monooxygenase antibody; (S)-limonene 6-monooxygenase antibody; (S)-limonene 7-monooxygenase antibody; CP2CJ_HUMAN antibody; CPCJ antibody; CYP2C antibody; CYP2C19 antibody; CYPIIC17 antibody; CYPIIC19 antibody; Cytochrome P-450 II C antibody; Cytochrome P450 2C19 antibody; Cytochrome P450; subfamily IIC (mephenytoin 4-hydroxylase); polypeptide 19 antibody; Cytochrome P450-11A antibody; Cytochrome P450-254C antibody; Flavoprotein-linked monooxygenase antibody; Mephenytoin 4 hydroxylase antibody; Mephenytoin 4-hydroxylase antibody; Microsomal monooxygenase antibody; P450-11A antibody; P45011A antibody; P450C2C antibody; S-mephenytoin 4-hydroxylase antibody; Xenobiotic monooxygenase antibody
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human, Mouse
  • 免疫原：
    Recombinant Human Cytochrome P450 2C19 protein (245-353AA)
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated

    本頁(yè)面中的產(chǎn)品，CYP2C19 Antibody (CSB-PA006417LA01HU)，的標(biāo)記方式是Non-conjugated。對(duì)于CYP2C19 Antibody，我們還提供其他標(biāo)記。見(jiàn)下表：

    可提供標(biāo)記
    標(biāo)記方式 貨號(hào) 產(chǎn)品名稱 應(yīng)用
    HRP CSB-PA006417LB01HU CYP2C19 Antibody, HRP conjugated ELISA
    FITC CSB-PA006417LC01HU CYP2C19 Antibody, FITC conjugated
    Biotin CSB-PA006417LD01HU CYP2C19 Antibody, Biotin conjugated ELISA
  • 克隆類型：
    Polyclonal
  • 抗體亞型：
    IgG
  • 純化方式：
    >95%, Protein G purified
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, WB, IHC, IF
  • 推薦稀釋比：
    Application Recommended Dilution
    WB 1:500-1:5000
    IHC 1:300-1:500
    IF 1:50-1:200
  • Protocols：
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position. Catalyzes the epoxidation of double bonds of PUFA. Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol. Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position.
  • 基因功能參考文獻(xiàn)：
    1. The frequency distribution of alleles CYP2C19 in Yakuts is between that in the representatives of Mongoloid and Caucasian races, which can be explained by the history of forming the population of this particular region. PMID: 29738309
    2. The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes. PMID: 29733119
    3. CYP2C19*2 genotype-guided antiplatelet treatment remained a cost-effective strategy. PMID: 28117433
    4. CYP2C19 SNP was significantly associated with high on-treatment platelet reactivity and clinical outcomes after percutaneous coronary intervention. PMID: 29352151
    5. Polymorphisms of the CYP2C19 is associated with Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-Hematopoietic Stem Cell Transplantation. PMID: 28685218
    6. In a subject with predicted CYP2C19 PM phenotype, the PK of BMS-823778 was affected significantly by UGT1A4 polymorphism. PMID: 29311135
    7. Wild-type CYP2C19*1B and 30 isoforms were highly expressed in insect cells, and the enzymatic activities of CYP2C19 variants towards nebivolol hydroxylation were characterized. Three variants, CYP2C19*29 (K28I), L16F, and CYP2C19*23 (G91R), showed increased intrinsic clearance of >140% CYP2C19*1B. PMID: 29098786
    8. Carriage of a combination of mutant alleles in multiple genes including ITGB3+CYP2C19*2 or CYP2C19*2 + ITGA2 or CYP2C19*2 are possible predictors of CVE in patients after CABG PMID: 29461866
    9. Gene polymorphism testing results indicated that patients with CYP2C19*3 had a significantly higher incidence of high on-treatment platelet reactivity. PMID: 29397568
    10. CYP2C19 genotype only partially determines the CYP2C19 phenotypic appearance. PMID: 29665549
    11. appears that 5azaDC treatment affects an unidentified upstream regulator of both CYP2C19 and/or NR1I3. This is supported by the fact that the relationships between TF for CYP2C19 and the expression of this target gene in human liver samples only accounted for approximately 70% of the variability of CYP2C19 mRNA levels. PMID: 28840784
    12. For percutaneous coronary intervention in postoperative patients, research data is still lacking regarding clopidogrel dosage on the basis of different CYP2C19 genotypes. PMID: 28164572
    13. Even heterozygous CYP2C19*2 allele carriers among Caucasian patients after ischemic stroke had a higher risk of major adverse clinical events. PMID: 29509167
    14. results obtained from this study have proven the CYP variants to be immunoreactive and spectrally active and are suitable for use to examine biotransformation and interaction mechanism of the enzymes PMID: 29524040
    15. Report association of CYP2C19 genotype with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. PMID: 29260275
    16. Personalized treatment with clopidogrel or ticagrelor based on CYP2C19 genotype status ultimately led to improved clinical outcomes in acute coronary syndrome patients treated with percutaneous coronary intervention. PMID: 29243114
    17. CYP2C19*2 Polymorphism is associated with drug resistance in Breast Cancer. PMID: 29479969
    18. Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2D6 = cytochrome P450 family 2 subfamily D member 6) PMID: 29181698
    19. We documented a different effect of CYP2C19 and P2Y12 receptor polymorphisms on platelet reactivity and cardiovascular outcome in coronary artery disease patients after percutaneous coronary intervention on clopidogrel treatment. Importantly, increased platelet reactivity adversely affects the cardiovascular outcome independently of the studied polymorphisms. PMID: 28329746
    20. CYP2C19*2 and elevated BMI are associated with clopidogrel HTPR. However, CYP2C19*2 genotyping doesn't predict clopidogrel response sufficiently. PMID: 28802144
    21. Results suggest a role of cytochrome P450 2C19 (CYP2C19) gene variants as a potential marker of Clopidogrel response. PMID: 29347970
    22. There is an association between cyp2c19 and loss of function allele status of clopidrogrel for stroke risk reduction PMID: 29979852
    23. The identified allele frequencies were CYP2C19*1 (64.33%), *2 (31.06%) and *3 (4.61%). The major prevalent genotype combinations were CYP2C19 *1/*1 (41.73%) and *1/*2 (39.65%). In the Hakka population, frequencies of the CYP2C19 *2 and *3 variants were observed to be close to those previously identified in Chinese and several other Asian populations. PMID: 29288619
    24. CYP2C19 polymorphisms significantly impacted systemic exposure and metabolism pathways of BMS-823778 in humans. PMID: 28850715
    25. Human but not rat liver proteins immunoblotting allowed us to characterize the novel LM antibodies and to identify CYP-2C19 as human antigen PMID: 29279846
    26. The frequency of primary outcome was significantly higher in patients carrying CYP2C19*2 AG/AA genotype receiving PPIs compared with the same genotype in those not receiving PPIs. The PPIs used in patients carrying CYP2C19*2 AG/AA was independently associated with the primary outcome after adjusting for other risk factors. PMID: 27637911
    27. PPI therapy in children with *17 alleles may be better optimized with CYP2C19 genotype-guided dosing prior to pH probe testing. PMID: 28884817
    28. Patients with CYP2C19*2 were at increased risk and CYP2C19*2, CYP3A5*3 and GSTP1 have synergistic influence on CYC failure. PMID: 28976264
    29. Consensus has yet to be reached on which CYP2D6 and CYP2C19 star alleles to include on pharmacogenetic testing panels and pharmacogenetic results reporting could be considerably improved PMID: 28777243
    30. The impact of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple eradication therapy in Slavic patients appears significant. PMID: 29889439
    31. A total of 42.0% carried >/=1 CYP2C19*2 allele. PMID: 28745576
    32. Implementing a CYP2C19 genotype-guided approach to antiplatelet therapy. PMID: 28745582
    33. Among children with medically refractory GERD despite proton pump inhibitor therapy, carriage of CYP2C19*17 allele corresponding to the extensive metabolizer phenotype was associated with need for anti-reflux surgery. PMID: 29209919
    34. Patients with an acute coronary event and a very poor, poor and normal CYP2C19 metabolizer genotype have a higher prevalence of diabetes mellitus needing insulin than patients with the rapid and ultrarapid metabolizers CPY2C19 genotype. PMID: 28473221
    35. In addition to the CYP2C19 genotype as predictive factors. PMID: 28834922
    36. no association was identified between the CYP2C19()2 variant and the development of coronary in-stent restenosis. PMID: 28785581
    37. CYP2C19 genetic polymorphisms had significant influence on the antiplatelet effect of clopidogrel and clinical outcomes in patients with intracranial aneurysms treated with stent-assisted coiling. PMID: 27634953
    38. The ultrarapid-metabolizing *17 allele of CYP2C19 (OMIM 124020), which is common in Europeans and Africans and rare in Asians, results in higher circulating concentrations of VNO. We hypothesized that LTRs with the *17 allele would have an increased risk for voriconazole-associated SCC. PMID: 26982740
    39. This gastric juice-based real-time PCR assay is a more accurate method for detecting H. pylori infection, clarithromycin susceptibility and CYP2C19 polymorphisms. The method may be employed to inform the choice of proton pump inhibitor (PPI), clarithromycin and amoxicillin treatment for tailored H. pylori eradication therapy PMID: 28638276
    40. This study showed that distinct genetic markers were associated with phenotype-specific PHT-induced severe cutaneous adverse drug reactions. HLA-B*13:01, HLA-B*56:02/04, and CYP2C19*3 were potential genetic markers of phenytoin-induced drug rash with eosinophilia and systemic symptoms/drug hypersensitivity syndrome in Thai patients. PMID: 28391407
    41. The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication. PMID: 28577017
    42. efficacy of clopidogrel for the prevention of ischemic stroke in post-coronary stent patients may be reduced by the insufficiency of the CYP2C19 gene PMID: 29188612
    43. These data highlight the potential relevance of CYP2C19 pharmacogenetics in influencing NorEND concentrations in tamoxifen-treated patients, which may influence treatment outcomes PMID: 26799162
    44. We compared the carrier frequency of Cytochrome P450 Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19*17, CYP2C9*3, ABCB1 (C3435T), SLCO1B1*5 were found between the Russian population and the three ethnic groups of the Dagestan republic. PMID: 29023140
    45. SNP rs4244285 of CYP2C19 tended to be associated with decreased risk of essential hypertension. PMID: 28513222
    46. CYP2C19 polymorphism analysis may improve treatment decisions in patients with ACS receiving DES-PCI PMID: 29279531
    47. Our results suggest that CYP2C19 LOF alleles (*2 and *3) significantly impact the prognosis of patients on clopidogrel therapy after CAS and that the CYP2C19*2 and CYP2C19*3 alleles have the same effects on prognosis PMID: 27137706
    48. Behcet's disease patients had lower CYP2C19 enzyme activity and lower frequency of the CYP2C19*17 allele as compared to those of the healthy controls. PMID: 27875029
    49. CYP2C19 polymorphism does not affect rosuvastatin pharmacokinetics in healthy Taiwanese in a clinically meaningful way. PMID: 27128002
    50. On-treatment platelet reactivity was compared between patients stratified by diabetes mellitus (DM), CYP2C19*2 status and clopidogrel dose. Both DM and CYP2C19*2 were independently associated with elevated on-treatment platelet reactivity with clopidogrel 75 mg daily. PMID: 27009617

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
  • 蛋白家族：
    Cytochrome P450 family
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 2621

    OMIM: 124020

    KEGG: hsa:1557

    STRING: 9606.ENSP00000360372

    UniGene: Hs.282409